CRP and myocarditis: Evidence is limited to small studies, case reports, and trials in related conditions, such as COVID-19 myocarditis, immune checkpoint inhibitor (ICI)-associated myocarditis, or post-MI inflammation, which show potential benefits in reducing CRP and improving ejection fraction but lack robust outcome data.